Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lucky STAR: FDA’s eSTAR Pilot Aims To Make 510(k) Process Smoother

Executive Summary

Nine device makers will soon have the chance to enroll in a voluntary eSTAR pilot program that the US agency says will make the premarket review process more efficient and consistent. The design and structure of an electronic Submission Template And Resource – or eSTAR – template is similar to templates used by FDA reviewers. An eSTAR won’t change the agency’s statutory or data requirements for sponsors to show substantial equivalence to predicate devices.

You may also be interested in...



New FDA Guidance Offers Additional Info On eStar Submissions

The US Food and Drug Administration says its guidance for manufacturers seeking premarket clearance is part of the agency’s overall commitment to improve e-submission consistency and enhance the review process.

FDA eSTAR Update: 51 Submissions, No Manufacturer Complaints

US FDA biomedical engineer Patrick Axtell gave an update on the streamlined 510(k) submission program at MedCon 2021.

Not So Fast: FDA Announces End Of QUIK 510(k) Pilot

The pilot program from the US agency is set to close on 30 May after regulators found the competing eSTAR project offered more advantages.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel